NZ209962A - Stable, crystalline form of prazosin hydrochloride - Google Patents
Stable, crystalline form of prazosin hydrochlorideInfo
- Publication number
- NZ209962A NZ209962A NZ209962A NZ20996284A NZ209962A NZ 209962 A NZ209962 A NZ 209962A NZ 209962 A NZ209962 A NZ 209962A NZ 20996284 A NZ20996284 A NZ 20996284A NZ 209962 A NZ209962 A NZ 209962A
- Authority
- NZ
- New Zealand
- Prior art keywords
- prazosin hydrochloride
- stable
- crystalline
- anhydrous
- prazosin
- Prior art date
Links
- 229960002386 prazosin hydrochloride Drugs 0.000 title claims description 31
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 title claims description 31
- 238000000034 method Methods 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000002329 infrared spectrum Methods 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010533 azeotropic distillation Methods 0.000 claims description 5
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 4
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI842544A FI79107C (fi) | 1984-06-25 | 1984-06-25 | Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ209962A true NZ209962A (en) | 1987-06-30 |
Family
ID=8519293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ209962A NZ209962A (en) | 1984-06-25 | 1984-10-23 | Stable, crystalline form of prazosin hydrochloride |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4739055A (enExample) |
| JP (1) | JPS6115881A (enExample) |
| AT (1) | AT389117B (enExample) |
| AU (1) | AU566814B2 (enExample) |
| BE (1) | BE900925A (enExample) |
| CH (1) | CH661045A5 (enExample) |
| DE (1) | DE3429415A1 (enExample) |
| FI (1) | FI79107C (enExample) |
| FR (1) | FR2567124B1 (enExample) |
| GB (1) | GB2160861B (enExample) |
| IL (1) | IL73267A (enExample) |
| IT (1) | IT1224142B (enExample) |
| LU (1) | LU85616A1 (enExample) |
| NL (1) | NL8403250A (enExample) |
| NZ (1) | NZ209962A (enExample) |
| PT (1) | PT79411B (enExample) |
| ZA (1) | ZA85910B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE72244T1 (de) * | 1986-03-21 | 1992-02-15 | Heumann Pharma Gmbh & Co | Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung. |
| JP2756846B2 (ja) * | 1989-12-28 | 1998-05-25 | 住化ファインケム株式会社 | 無水のε型結晶体２―〔４―（２―フロイル）ピペラジン―１―イル〕―４―アミノ―６，７―ジメトキシキナゾリン塩酸塩及びその製造方法 |
| JPH07206857A (ja) * | 1993-12-28 | 1995-08-08 | Synthelabo Sa | アルフゾシン塩酸塩の二水和物 |
| SK286975B6 (sk) * | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) * | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CA2696579C (en) * | 2007-08-17 | 2017-01-24 | Boehringer Ingelheim International Gmbh | Purine derivatives for use in the treatment of fab-related diseases |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| NZ604091A (en) * | 2008-08-15 | 2014-08-29 | Boehringer Ingelheim Int | Purin derivatives for use in the treatment of fab-related diseases |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2969375A (en) * | 1961-01-24 | Certification of correction | ||
| DE156532C (enExample) * | ||||
| BE427505A (enExample) * | 1937-05-25 | |||
| GB1156973A (en) * | 1965-07-06 | 1969-07-02 | Quinazoline Derivatives | |
| US3433788A (en) * | 1966-04-27 | 1969-03-18 | Union Carbide Corp | Process for recovery of amines from aqueous solutions by solvent treatment and distillation |
| US3421983A (en) * | 1967-03-07 | 1969-01-14 | Lummus Co | Azeotropic distillation of aqueous toluene diamine |
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| US3743672A (en) * | 1970-05-27 | 1973-07-03 | Halcon International Inc | Separation of water in alkylene glycol mono and diester purification by azeotropic distillation |
| GB1308718A (en) * | 1970-07-01 | 1973-03-07 | Sir Soc Italiana Resine Spa | Method of separating vinyl acetate from liquid mixtures |
| IT956765B (it) * | 1972-06-22 | 1973-10-10 | Montedison Spa | Procedimento per la purificazione di 1 3 diossolano |
| US3935213A (en) * | 1973-12-05 | 1976-01-27 | Pfizer Inc. | Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4001237A (en) * | 1976-02-18 | 1977-01-04 | Bristol-Myers Company | Oxazole, isoxazole, thiazole and isothiazole amides |
| US4092315A (en) * | 1976-03-01 | 1978-05-30 | Pfizer Inc. | Novel crystalline forms of prazosin hydrochloride |
| FI67699C (fi) * | 1979-01-31 | 1985-05-10 | Orion Yhtymae Oy | Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan |
| FI64367C (fi) * | 1980-02-26 | 1986-08-05 | Orion Yhtymae Oy | Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid |
-
1984
- 1984-06-25 FI FI842544A patent/FI79107C/fi not_active IP Right Cessation
- 1984-08-09 DE DE19843429415 patent/DE3429415A1/de active Granted
- 1984-10-03 GB GB08424999A patent/GB2160861B/en not_active Expired
- 1984-10-15 US US06/660,871 patent/US4739055A/en not_active Expired - Lifetime
- 1984-10-19 AU AU34510/84A patent/AU566814B2/en not_active Ceased
- 1984-10-19 IL IL73267A patent/IL73267A/xx not_active IP Right Cessation
- 1984-10-23 NZ NZ209962A patent/NZ209962A/en unknown
- 1984-10-24 IT IT23292/84A patent/IT1224142B/it active
- 1984-10-25 NL NL8403250A patent/NL8403250A/nl not_active Application Discontinuation
- 1984-10-26 CH CH5142/84A patent/CH661045A5/de not_active IP Right Cessation
- 1984-10-26 FR FR8416401A patent/FR2567124B1/fr not_active Expired - Lifetime
- 1984-10-26 PT PT79411A patent/PT79411B/pt not_active IP Right Cessation
- 1984-10-29 BE BE0/213911A patent/BE900925A/fr not_active IP Right Cessation
- 1984-10-29 JP JP59227640A patent/JPS6115881A/ja active Granted
- 1984-10-29 LU LU85616A patent/LU85616A1/fr unknown
- 1984-10-30 AT AT0344184A patent/AT389117B/de not_active IP Right Cessation
-
1985
- 1985-02-06 ZA ZA85910A patent/ZA85910B/xx unknown
-
1988
- 1988-02-08 US US07/153,780 patent/US4873330A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB2160861B (en) | 1987-11-18 |
| FI79107C (fi) | 1989-11-10 |
| ZA85910B (en) | 1985-09-25 |
| LU85616A1 (fr) | 1985-06-04 |
| US4739055A (en) | 1988-04-19 |
| CH661045A5 (de) | 1987-06-30 |
| IT1224142B (it) | 1990-09-26 |
| FI842544A0 (fi) | 1984-06-25 |
| JPH0481993B2 (enExample) | 1992-12-25 |
| PT79411B (en) | 1986-09-15 |
| ATA344184A (de) | 1989-03-15 |
| FR2567124B1 (fr) | 1990-09-21 |
| IL73267A (en) | 1988-06-30 |
| FI842544L (fi) | 1985-12-26 |
| AU3451084A (en) | 1986-01-02 |
| DE3429415C2 (enExample) | 1990-05-03 |
| US4873330A (en) | 1989-10-10 |
| FI79107B (fi) | 1989-07-31 |
| AU566814B2 (en) | 1987-10-29 |
| GB2160861A (en) | 1986-01-02 |
| AT389117B (de) | 1989-10-25 |
| NL8403250A (nl) | 1986-01-16 |
| IT8423292A0 (it) | 1984-10-24 |
| IL73267A0 (en) | 1985-01-31 |
| PT79411A (en) | 1984-11-01 |
| FR2567124A1 (fr) | 1986-01-10 |
| BE900925A (fr) | 1985-02-15 |
| DE3429415A1 (de) | 1986-01-02 |
| GB8424999D0 (en) | 1984-11-07 |
| JPS6115881A (ja) | 1986-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ209962A (en) | Stable, crystalline form of prazosin hydrochloride | |
| US4721723A (en) | Anti-depressant crystalline paroxetine hydrochloride hemihydrate | |
| US4816455A (en) | Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation | |
| EP1956015B2 (en) | Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same | |
| KR20010013615A (ko) | 4-페닐피페리딘 화합물 | |
| ITMI20011726A1 (it) | Forme polimorfe della lercanidipina cloridrato | |
| KR20110017936A (ko) | 퀴놀린 화합물의 결정형 및 그의 제조 방법 | |
| KR20070105299A (ko) | 레트로졸의 제조를 위한 개선된 방법 | |
| PL135475B1 (en) | Method of obtaining novel benzamide derivatives | |
| EP1345903A1 (en) | Crystalline forms of cerivastatin sodium | |
| WO2000078729A1 (en) | Crystalline forms of lansoprazole | |
| US20050272775A1 (en) | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof | |
| FI110777B (fi) | Menetelmä 7-[7-(S)-amino-5-atsaspiro[2.4]heptan-5-yyli]-8-kloori-6-fluori-1-[(1R,2S)-2-fluorisyklopropyyli]-4-okso-1,4-dihydrokinoliini-3-karboksyylihapon 3/2-hydraatin saamiseksi selektiivisesti | |
| JPS6147820B2 (enExample) | ||
| NL8203688A (nl) | Nieuwe kristalmodificatie van cimetidine, alsmede werkwijze voor de bereiding ervan. | |
| EP1903046B1 (en) | New clopidogrel salt and its crystalline forms | |
| US20050288330A1 (en) | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) | |
| HU188074B (en) | Process for the preparation of cimetidin | |
| HU194179B (en) | Process for production of 1-/3',4'-dietoxi-benzil/-1,6,7-dietoxi-3,4-dihydro-izoquinolinine-teophilin-7-acetate and their new cristallic monohydrate | |
| GB2097791A (en) | Quaternary ammonium salt | |
| US4889929A (en) | Preparation of 1'-ethoxycarbonyl-oxyethyl esters of penicillins | |
| DK175352B1 (da) | Fremgangsmåde til fremstilling af 4-phenylpiperidinderivater | |
| DE2225762B2 (de) | Substituierte Fusarsäuren und Derivate derselben sowie Verfahren zur Herstellung derselben und Arzneimittel mit einem Gehalt derselben | |
| JPH0631302B2 (ja) | エトポシド−２−ジメチルアミノ体塩酸二水和結晶及びその製造法 | |
| JP2008510797A (ja) | ４−フルオロ−α−［２−メチル−１−オキソプロピル］γ−オキソ−Ｎ−β−ジフェニルベンゼンブタンアミドの製造方法 |